Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.16+0.15 (+0.88%)
Close on Nov 13, 2026Market cap $3.20BP/E –Yield –
Dyne Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Dyne Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$564.53M. For fiscal 2025 it was -$403.21M. The highest annual figure on record is -$11.83M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$403.21M | – |
| FY2024 | Dec 31, 2024 | -$292.37M | – |
| FY2023 | Dec 31, 2023 | -$188.16M | – |
| FY2022 | Dec 31, 2022 | -$153.65M | – |
| FY2021 | Dec 31, 2021 | -$119.56M | – |
| FY2020 | Dec 31, 2020 | -$46.51M | – |
| FY2019 | Dec 31, 2019 | -$11.83M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$177.49M | – |
| Q2 FY2026 | Jun 30, 2026 | -$130.29M | – |
| Q1 FY2026 | Mar 31, 2026 | -$144.92M | – |
| Q4 FY2025 | Dec 31, 2025 | -$111.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$90.78M | – |
| Q2 FY2025 | Jun 30, 2025 | -$94.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$105.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$84.34M | – |
| Q3 FY2024 | Sep 30, 2024 | -$74.63M | – |
| Q2 FY2024 | Jun 30, 2024 | -$54.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$78.54M | – |
| Q4 FY2023 | Dec 31, 2023 | -$35.01M | – |
| Q3 FY2023 | Sep 30, 2023 | -$50.60M | – |
| Q2 FY2023 | Jun 30, 2023 | -$55.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$46.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$42.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.91M | – |
| Q1 FY2022 | Mar 31, 2022 | -$50.74M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.07M | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.95M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.15M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.39M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.04M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.89M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.30M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.29M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.01M | – |
See a number that looks wrong?